---
title: "\"Performance\" DEEWIN's annual net profit is RMB 68.29 million, a decrease of 55.4%, with a dividend of 31.47 cents per 10 shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280911182.md"
description: "DEEWIN announced its 2025 annual performance, with revenue of 2.762 billion RMB, an increase of 5.1% year-on-year. It recorded a net profit of 68.29 million RMB, a decline of 55.4%, with earnings per share of 0.03 RMB. The final dividend is 3.147 RMB per 10 shares"
datetime: "2026-03-29T13:04:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280911182.md)
  - [en](https://longbridge.com/en/news/280911182.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280911182.md)
generator: "portal-rs"
---

# "Performance" DEEWIN's annual net profit is RMB 68.29 million, a decrease of 55.4%, with a dividend of 31.47 cents per 10 shares

DEEWIN (02418.HK) announced its 2025 annual results, with revenue of 2.762 billion RMB, an increase of 5.1% year-on-year. It recorded a net profit of 68.29 million RMB, a decline of 55.4%, with earnings per share of 0.03 RMB. The final dividend is 31.47 RMB for every 10 shares

### Related Stocks

- [02418.HK](https://longbridge.com/en/quote/02418.HK.md)

## Related News & Research

- [US families, healthcare providers under strain after Trump crackdown on Haitian immigrants](https://longbridge.com/en/news/296335867.md)
- [US health agencies report 55 cases of E. coli and salmonella infections tied to alfalfa sprouts](https://longbridge.com/en/news/296645342.md)
- [Kakao to spin off chat app-based platform business into KakaoAI, relist in 2027](https://longbridge.com/en/news/296558074.md)
- [CSPC PHARMA  Shares Rise 15% as Phase Ib/II Clinical Trial of SYS 6090 Injection for Hepatocellular Carcinoma Launches at First Center in China](https://longbridge.com/en/news/296423040.md)
- [POP MART Gaps Down 8.2% at Open as Interim Results Miss w/ Plans of Share Buyback of Up to RMB5B](https://longbridge.com/en/news/296555795.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**